HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

STVN

Stevanato Group S.p.A. (NYSE)

Healthcare — Medical Instruments & Supplies

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass converting machines; and after-sales services, such as line optimization and line conversions, training, logistics, spare parts and maintenance services. It also provides contract development and manufacturing services for customer-owned drug delivery devices. The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug products, glass packaging, and fill and finish contract manufacturers. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.

None 10 analysts
$19.37
+$0.27 (+1.41%)
Target: $24.45 (26.2%)
Sign in to add STVN to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$5.01B
P/E Ratio (TTM)31.62
Forward P/E21.89
EPS (TTM)$0.58
Dividend Yield0.34%
Profit Margin11.75%
Revenue Growth6.60%
ROE9.59%
Debt/Equity29.43
Recommendation None
Analyst Target$24.45
Analysts10
Indexes NYSE

Technical Indicators

RSI (14)59.0
Beta0.78
SMA 20-
SMA 40-
52-Week High$28.00
52-Week Low$12.89
50-Day Avg$17.60
200-Day Avg$19.40
Avg Volume402.0K
Volume185.9K

Performance Analysis

BULLISH

STVN shows predominantly bullish signals based on its fundamentals and technicals.

~ Trading at 43% of its 52-week range.
+ RSI at 59.0 shows positive momentum.
~ Modest revenue growth of 6.6% year-over-year.
~ Wall Street consensus is "none" from 10 analysts.
+ Average analyst target of $24.45 implies 26.2% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:33 UTC

Back to Screener Export Report